Precision BioSciences Inc (DTIL) stock
Close on Nov 17, 2026Market cap $194.59MP/E –Yield –
Precision BioSciences Inc grew revenue 3473.0% to $45.06M over the twelve months to Jun 30, 2026. Free cash flow was -$51.94M. At the latest close the market valued the company at $194.59M.
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Jun 30, 2026
Valuation
- Market cap
- $194.59M
- P/E ratio
- –
- Price to sales
- 4.32
- Price to book
- 4.30
- Dividend yield
- –
- Free cash flow yield
- -26.69%
Fundamentals
- Revenue
- $45.06M
- Net income
- -$52.73M
- EPS, diluted
- -$3.56
- Free cash flow
- -$51.94M
- Book value per share
- $1.75
- Diluted shares
- 26M
Trading
- Next earnings
- Mar 11, 2027 (estimated, before the open)
- Previous close
- $7.28
- Open
- $7.26
- Day's range
- $6.88 – $7.46
- Volume
- 350,990
- Average volume (20 days)
- 447,595
- Index membership
- Russell 2000 (since Jun 2026)
- 52-week range
- $3.53 – $11.29
- RSI (14 days)
- 46.4
- Volatility (1 year)
- 75.0%
- Relative volume
- 0.64×
Index membership is inferred from the holdings of funds that track each index (IWM), as reported to the SEC for Jun 30, 2026. Join dates come from quarterly fund reports since 2019, so they are accurate to the quarter.
Market cap history
Month-end market cap since 2019, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 17, 2026. The S&P 500 is measured by the SPY fund.
| Period | DTIL | S&P 500 | Difference | DTIL per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | +22.2% | -4.0% | +26.2 pts | ||
| 3 months | -4.7% | -5.0% | +0.2 pts | ||
| Year to date | +69.5% | +8.2% | +61.2 pts | ||
| 1 year | +37.2% | +11.2% | +25.9 pts | ||
| 3 years | -46.2% | +68.5% | −114.7 pts | -18.7% | +19.0% |
| 5 years | -97.6% | +67.3% | −164.9 pts | -52.5% | +10.8% |
Nine years at a glance
Fiscal years 2017 to 2025 and trailing twelve months, USD
Revenue
Operating income
Net income
EPS, diluted
Free cash flow
Press releases
Releases Precision BioSciences filed with the SEC as exhibits to Form 8-K or 6-K
- News
- Update
- Update
- Update
- Results
- Update
About Precision BioSciences
Biological Products, (No Diagnostic Substances)
The company is a clinical-stage genome editing biotechnology company that develops in vivo gene editing therapies using its proprietary ARCUS platform. Its technology enables complex genetic modifications, such as inserting functional genes, eliminating viral genomes, and excising defective genetic sequences. The company's primary internal drug candidates include PBGENE-HBV, aimed at treating chronic hepatitis B by eliminating viral DNA, and PBGENE-DMD, designed to treat Duchenne muscular dystrophy through targeted gene excision. Additionally, the company collaborates with external pharmaceutical partners on programs such as ECUR-506 for ornithine transcarbamylase deficiency, and licenses its technology for therapeutic research and development. Its end customers and beneficiaries are patients suffering from severe genetic disorders and infectious diseases.
Company profile, executives and historyPrecision BioSciences stock: common questions
What is Precision BioSciences's stock price?
DTIL closed at $7.05 on Nov 17, 2026, down 3.16% on the day. Over the past 52 weeks it traded between $3.53 and $11.29.
What is Precision BioSciences's market cap?
Precision BioSciences was worth $194.59M at the close on Nov 17, 2026: the share price times the diluted shares outstanding.
What is DTIL's P/E ratio?
Precision BioSciences lost money over fiscal 2025 (diluted EPS -$3.56), so it has no meaningful P/E ratio.
How much revenue does Precision BioSciences make?
Precision BioSciences reported revenue of $45.06M for the twelve months to Jun 30, 2026, up 3473.0% from a year earlier.
Does Precision BioSciences pay a dividend?
No. Precision BioSciences has not paid a cash dividend over the last twelve months.
When does Precision BioSciences report earnings next?
Precision BioSciences is expected to report Q4 FY2026 results on Mar 11, 2027, before the open. The date is estimated from its past reporting pattern until the company confirms it.
How has DTIL stock performed over the past year?
Including dividends, DTIL returned +37.2% over the past year, against +11.2% for the S&P 500.
How many DTIL shares are sold short?
2M shares were sold short at the latest FINRA report, 7.83% of the float, or 10.5 days of average trading volume.
Who are Precision BioSciences's competitors?
Companies most similar to Precision BioSciences by business, industry and size include EDIT, CRSP, SGMOQ, NTLA, MGX.
See a number that looks wrong?